A Disruptive Approach to Advancement: Strategic Investments and Collaborative Innovation to Solve Major Manufacturing Pain Points
![](https://www.phacilitate.com/wp-content/uploads/2021/09/georgi-makin_avatar-48x48.png)
SHARE NOW
Xavier De Mollerat Du Jeu, Senior Director R&D at Thermo Fisher Scientific is accompanied by Gianluca Pettiti, Executive Vice President and President, Life Sciences Group at Thermo Fisher Scientific and Fred Parietti, Co-Founder and CEO at Multiply Labs for this Workshop at Advanced Therapies Week 2024.
A key factor that promotes positive clinical outcomes in cell therapy manufacturing is the achievement of a younger, less differentiated T cell population at the outset of the manufacturing process. In this talk, you will hear about new flexible solutions that increase control over target cell isolation and activation steps upstream in the process while simultaneously providing process flexibility for steps downstream.
These new tools are designed to incorporate into a closed, scalable and automatable workflow, helping to streamline the process, with the potential to greatly reduce manufacturing timelines. This suite of modular instruments and tools spans the end-to-end workflow allowing the user greater flexibility and control of their process parameters to modulate the nuanced variables that affect end-point therapeutic efficacy.
This Workshop was produced in partnership with Thermo Fisher Scientific.